健脾疏肝利水法为主内外合治恶性腹腔积液

观察健脾疏肝利水为主的中医药内服外敷治疗恶性腹腔积液的疗效。设治疗组 3 8例采用内服中药加中药外敷腹部 ,配服西药利尿剂。对照组 2 7例 ,常规服西药利尿剂及对症治疗 ,疗程均为 1个月。结果 :治疗组有效率为65 7% ,对照组有效率为 48 1% (P <0 0 5 )。生存期 6个月以上、1年以上者 :治疗组分别为 12例、4例 ,对照组为 5例、0例。提示以中医药内外合治为主对恶性腹腔积液疗效明显高于单纯用西药利尿剂     

ANGIOTENSIN-CONVERTING ENZYME INHIBITION AS FIRST-LINE TREATMENT FOR HYPERTENSION

1. Perindopril (4 mg) was compared with atenolol (50 mg), captopril (25 mg b. d.) or a diuretic (hydrochlorothiazide 50 mg and amiloride 5 mg) in three studies involving a total of 503 hypertensive patients with a diastolic blood pressure (DBP) of 95–125 mmHg.
2. A 4 week single-blind placebo period preceded 12 weeks of active treatment. Dose titration was at weeks 4 and 8 if supine DBP >90 mmHg. The dose was doubled and if necessary a diuretic was added in the atenolol or captopril comparisons, and atenolol was added in the diuretic study.
3. The fall in supine blood pressure (BP) was 27/17 mmHg with perindopril and 21/16 mmHg for atenolol. Monotherapy controlled 55% of patients on perindopril and 48% on atenolol, increasing to 78% and 58% with the addition of hydrochlorothiazide, respectively. Captopril caused a BP fall of 19/12 mmHg compared with 27/18 mmHg for perindopril, with 49% of both groups being controlled on monotherapy.
4. Diuretic addition produced a greater antihypertensive effect with perindopril (75%) compared with 57% for captopril in achieving control. Perindopril caused a comparable fall in supine BP to the diuretic combination 27/19 mmHg and 31/18 mmHg, but the fall in erect systolic BP was significantly greater for the diuretic. At 3 months, 85% of the diuretic group and 78% of the perindopril group achieved the target BP.
5. A multicentre trial of 856 patients treated with perindopril (690 patients treated for 1 year or more) has shown that BP control is maintained in the long term with a low incidence of side-effects (7.9%) causing withdrawal from treatment. These studies demonstrate that perindopril compares favourably with standard first-line therapy for mild to moderate hypertension.     

感染性休克患者的负液体平衡与预后的关系

目的探究感染性休克治疗的前3天患者的液体平衡状态与预后的关系。方法采用回顾性对照研究。查看1999年1月至2003年12月收入首都医科大学附属复兴医院ICU的感染性休克患者病例记录,入选病例必须严格符合感染性休克的诊断标准,且既往无肾功能不全病史。采集病例相关数据以及诊断后第1、2、3天的液体平衡值。比较不同组别患者的急性生理和慢性健康评分(APACHEⅡ)、继发器官衰竭评分(SOFA)、液体平衡和病死率等数据。对影响患者预后的独立危险因素进行Logistic回归分析,确定和描述感染性休克患者的预后与在前3天的液体复苏治疗中出现的负平衡((0mL)相关因素的关系。结果负液体平衡患者与未出现负液体平衡患者2组的病死率差异有统计学意义(52.4%vs87.5%,χ2=5.303,P=0.021)。通过对入组时患者年龄、APACHEⅡ评分、第1天和第3天SOFA评分和正负平衡等影响患者预后的独立危险因素Logistic回归分析,表明前3天的治疗中,若有1d出现负液体平衡即可成为影响患者预后的独立危险因素(P=0.035)。结论在感染性休克前3天的治疗中,若有1d出现液体平衡负值即可成为影响感染性休克患者预后的独立因素,对感染性休克的28d生存预后有较强的预测性。在前3天的治疗中出现液体平衡为负值((0mL)的感染性休克患者的生存率比液体平衡为正值的患者的28d生存率高。     

The influence of diuretics on the excretion and metabolism of doping agents - I. Mephentermine

The urinary excretion of mephentermine and its major metabolite phentermine in human volunteers was followed over a period of several days after oral administration of mephentermine. The excretion of both substances was affected by urinary pH. Maximum excretion was observed 2-4 h after administration and the total proportion of mephentermine excreted during 54 h was 57 to 83%. Based on urinary values, the biological half-life of elimination of mephentermine was 9.9 +/- 2.6 h. The ingestion of acetazolamide shortly after administration of mephentermine resulted in a decrease in excretion of both mephentermine and phentermine during one day; in some instances, the amounts of these substances in the urine were below the detection limit for a period of 3-9 h. The administration of frusemide only produced a urinary diluting effect during 2-4 h after administration.     

Pharmacokinetics of high doses of piretanide in moderate to severe renal failure

Summary The pharmacokinetics of piretanide was studied in 10 patients with chronic renal failure. After administration of a high oral dose (12 to 192 mg) of piretanide the kinetics behaved according to an open 2-compartment model. The elimination constant in the first phase () ranged from 0.385 to 0.756 h^–1 and in the second phase () from 0.079 to 0.274 h^–1. The corresponding elimination half-lives ranged from 55 to 108 min (t_1/2 ) and from 152 to 524 min (t_1/2 ). Only an average of 2.8% of the orally administered drug was recovered in 24 h urines. Nevertheless, a good correlation was found between urinary recovery or renal clearance of the drug and residual renal function. The elimination of piretanide by non-renal mechanisms appeared to be increased when renal function was greatly diminished.     

茯苓对阴虚水肿模型大鼠及其热象的影响

目的 观察茯苓对阴虚水肿模型大鼠的影响,研究茯苓利水作用特点及机制,并评价茯苓对阴虚水肿所表现出热象的影响。方法 尾iv阿霉素联合ig甲状腺片复制阴虚水肿模型大鼠,给予茯苓水煎液或六味地黄丸干预4周,观察大鼠水肿情况和一般生长状态,检测24 h尿量和尿蛋白,测量肛温,进行冷热板实验计算热板停留时间比;检测血清总蛋白（total cholesterol,TP）、白蛋白（albumin,Alb）、尿素氮（blood urea nitrogen,BUN）、肌酐（creatinine,Cr）、环磷酸腺苷（cyclic adenosine monophosphate,c AMP）、环磷酸鸟苷（cyclic guanosine monophosphate,c GMP）水平;测定肾组织超氧化物歧化酶（superoxide dismutase,SOD）活性及活性氧（reactive oxygen species,ROS）、丙二醛（malondialdehyde,MDA）水平;苏木素-伊红（HE）染色观察肾组织病理变化;Western blotting检测肾脏组织Klotho和棕色脂肪组织中解偶联蛋白1...     

Sequential changes in plasma renin activity and plasma catecholamines in mildly hypertensive patients during acute,furosemide-induced body-fluid loss

Summary To evaluate the role of adrenergic mechanisms in the acute response of renin to furosemide, plasma renin activity (PRA) and plasma catecholamine concentrations were measured for 3 h after i.v. administration of furosemide 1 mg/kg to 8 patients with mild essential hypertension. Furosemide induced a prompt and long-lasting increase in renin, with PRA more than doubled at all times. The increase in PRA within the first 30 min paralleled the peak increases in urinary water and sodium flow rates, and significant decreases in plasma volume and central venous pressure. There was no change in plasma catecholamine concentrations. Plasma noradrenaline was increased significantly at 60 min and adrenaline at 90 min, once furosemide had induced a marked loss of body-fluid and 65% decrease in central venous pressure. Both catecholamines remained elevated until the end of the study, whereas urinary water and sodium flow rates had returned to their pre-treatment values by 150 min. Mean blood pressure was essentially unchanged throughout the study, whereas heart rate increased significantly after 90 min. The findings suggest that in mildly hypertensive patients adrenergic mechanisms are not involved in the initial renin response to furosemide, but they come into play later, probably as a result of reflex sympathetic activation triggered by marked volume depletion.     

托拉塞米的利尿作用和安全性

目的 观察健康受试者口服托拉塞米的利尿作用和安全性。方法 19名健康男性受试者单次口服不同剂量托拉塞米5,10和20 mg(n=9)或连续7天每日口服托拉塞米10 mg(n=10)。观察血压,尿量,24 h尿钾、钠、氯和血钾、钠、氯,心率,呼吸,心电图和心电监测,血常规,尿常规,血生化等指标。 结果 5,10,20mg 3组单次服药后24 h总尿量分别为2.24,2.60和3.17 L(P<0.05),24 h尿钾、钠、氯的排泄随托拉塞米剂量增加而略增加(P>0.05)。连续服药,首次药后的24h尿量及尿钾、钠、氯的量最多。单次和连续给药后血钾、钠、氯均未见下降,甘油三脂增加0.1~0.4 mmol.L-1(P<0.05)。4例受试者出现药物不良反应。 结论 在5~20 mg,托拉塞米利尿作用随剂量增加而增加,国人对托拉塞米耐受性良好。     

Pharmacokinetic Interaction of the Direct Renin Inhibitor Aliskiren with Furosemide and Extended‐Release Isosorbide‐5‐Mononitrate in Healthy Subjects

This study investigated the pharmacokinetics, safety, and tolerability of aliskiren administered alone or in combination with either the loop diuretic furosemide or an oral extended‐release formulation of isosorbide‐5‐mononitrate (ISMN). In separate studies, 22 healthy subjects (ages 18–45 years) received either ISMN 40 mg or furosemide 20 mg once‐daily for 3 days followed by a 3‐day washout. Subjects then received aliskiren 300 mg once‐daily for 7 days followed by combination therapy for 3 days. Pharmacokinetic assessments were taken at regular intervals over 24 h after dosing on the last day of each treatment period. At steady state, aliskiren AUC_τ was decreased by 7% (geometric mean ratio [90% CI], 0.93 [0.84, 1.04]), and C_max by 20% (0.80 [0.65, 0.97]) with furosemide coadministration compared with aliskiren administration alone. Aliskiren coadministration reduced furosemide AUC_τ by 28% (0.72 [0.64, 0.81]) and C_max by 49% (0.51 [0.39, 0.66]) compared with furosemide alone. Coadministration of aliskiren and ISMN was associated with only minor changes in the pharmacokinetic parameters of aliskiren (AUC_τ 1.03 [0.90, 1.18]; C_max 0.94 [0.69, 1.29]) and ISMN (AUC_τ 0.88 [0.71, 1.10]; C_max 0.94 [0.79, 1.13]). Headache and dizziness were the most common adverse events in both studies; dizziness and BP values below normal (SBP <90 and/or DBP <50 mmHg) were more frequent with aliskiren and ISMN coadministration than with either agent alone. Coadministration of aliskiren and ISMN had no clinically relevant effect on either aliskiren or ISMN pharmacokinetics. In conclusion, coadministration of aliskiren and furosemide reduced furosemide exposure and had a minor effect on aliskiren pharmacokinetics. The clinical significance of reduced systemic exposure to furosemide during coadministration of aliskiren is uncertain.